Prevention of Graft Rejection in Hematopoietic Stem Cell Transplant (HSCT) Recipients

Recruiting now · Early Phase 1

Conditions studied: Hematopoietic Stem Cell Transplantation, Graft Failure

In brief

The investigators hypothesize that graft rejection after hematopoietic stem cell transplant (HSCT) is primarily driven by interferon gamma, and prophylactic interferon gamma inhibition in high-risk patients will prevent graft rejection. Additionally, knowledge of emapalumab PK/PD and in vitro mechanistic effects of emapalumab in this novel setting will guide optimization of dosing regimens and treatment approaches in future studies.

Key facts

Study ID

NCT07244419

Run by

Children's Hospital Medical Center, Cincinnati

People needed

20

Starts

2026-01-07

Expected to finish

2029-08-01

Last updated by the study team

2026-01-22

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• All patients undergoing allogeneic HSCT at our institution will be evaluated for graft rejection risk factors. Patients deemed high risk for graft rejection will have 2 or more of the following: mismatched or haploidentical donor, ex vivo t-cell depleted graft, prior history of graft rejection.

You may not qualify if…

• Known hypersensitivity to any constituent of the study medication.

Where it is running

• Cincinnati Children's Hospital Medical Center — Cincinnati, Ohio, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.